251 related articles for article (PubMed ID: 17598435)
1. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
[TBL] [Abstract][Full Text] [Related]
3. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis].
Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Forkasiewicz Z; Dawiskiba J; Bednarz W; Domosławski P
Endokrynol Pol; 2006; 57(6):605-11. PubMed ID: 17253433
[TBL] [Abstract][Full Text] [Related]
5. Acetylator polymorphism in Alzheimer's disease.
Ladero JM; Barquero MS; Coria F; Molina JA; Jiménez-Jiménez FJ; Benítez J
Eur J Med; 1993 May; 2(5):281-3. PubMed ID: 8252158
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of the determination of oxidation and acetylation phenotype in patients with multiple sclerosis].
Milejski P; Orzechowska-Juzwenko K; Pawlik J; Kamienowski J; Horoch E; Niewiński P; Hurkacz M
Neurol Neurochir Pol; 1996; 30(4):571-9. PubMed ID: 9045059
[TBL] [Abstract][Full Text] [Related]
7. [Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer].
Orzechowska-Juzwenko K; Wiela-Hojeńska A; Milejski P; Cieślińska A; Hudziec P; Adamska M
Przegl Lek; 1997; 54(2):103-6. PubMed ID: 9198818
[TBL] [Abstract][Full Text] [Related]
8. Acetylator phenotype in patients with allergic diseases and its clinical significance.
Orzechowska-Juzwenko K; Milejski P; Patkowski J; Nittner-Marszalska M; Malolepszy J
Int J Clin Pharmacol Ther Toxicol; 1990 Oct; 28(10):420-5. PubMed ID: 2258251
[TBL] [Abstract][Full Text] [Related]
9. [Oxidation phenotype as a risk factor for development of allergic diseases].
Niewiński P; Orzechowska-Juzwenko K; Patkowski J; Wolańczyk-Medrala A; Nittner-Marszalska M; Rzemisławska Z
Pol Arch Med Wewn; 1999 Jan; 101(1):23-7. PubMed ID: 10592724
[TBL] [Abstract][Full Text] [Related]
10. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
[TBL] [Abstract][Full Text] [Related]
11. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
12. Oxidative phenotype polymorphism (P450 2D6) and metabolism of toluene.
Pelclová D; Mráz J; Patzelová V; Pícková J; Pospísil J; Vodicková L; Hornychová M; Vejlupková J
Int J Clin Pharmacol Ther; 1996 Jan; 34(1):38-42. PubMed ID: 8688995
[TBL] [Abstract][Full Text] [Related]
13. N-acetylation phenotyping with sulfamethazine in an Iranian population.
Sardaş S; Lahijany B; Cok I; Karakaya AE
Pharmacogenetics; 1993 Jun; 3(3):131-4. PubMed ID: 8334437
[TBL] [Abstract][Full Text] [Related]
14. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
Ylitalo P; Auterinen L; Marttinen A; Koivula T
Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms].
Wiela-Hojeńska A; Milejski P; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Urbaniak-Kujda D; Kotlarek-Haus S
Przegl Lek; 1997; 54(3):163-6. PubMed ID: 9297191
[TBL] [Abstract][Full Text] [Related]
16. [Occurrence of the fast acetylation phenotype in persons with the radicular syndrome. Preliminary report].
Milejski P; Orzechowska-Juzwenko K; Tota B; Krzysztoń Z
Neurol Neurochir Pol; 1987; 21(6):511-5. PubMed ID: 3449771
[TBL] [Abstract][Full Text] [Related]
17. Polymorphic N-acetylation of sulfamethazine and benzidine by human liver: implication for cancer risk?
Peters JH; Gordon GR; Lin E; Green CE; Tyson CA
Anticancer Res; 1990; 10(1):225-9. PubMed ID: 2334132
[TBL] [Abstract][Full Text] [Related]
18. Oxidative phenotype status in related subjects.
Rychlik-Sych M; Łyczba M; Skretkowicz J
Acta Pol Pharm; 2008; 65(1):165-8. PubMed ID: 18536192
[TBL] [Abstract][Full Text] [Related]
19. [Acetylation phenotype in Graves' disease].
Górnik W; Syrenicz A; Gawrońska-Szklarz B; Wójcicki J
Pol Tyg Lek; 1989 Aug 7-14; 44(32-33):743-5. PubMed ID: 2641798
[TBL] [Abstract][Full Text] [Related]
20. Hepatic acetylator phenotype in bladder cancer patients.
Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
